Glaucoma Today

01/12/2026

Make sure you're up to date on approved, investigational, and emerging treatment options for your glaucoma patients with the new 2026 Glaucoma Pipeline poster.

Learn More: https://ow.ly/f0Ah50XQmEk

12/29/2025

In the latest episode of Glaucoma Case Files, discover how experts at the John A. Moran Eye Center approach trabeculectomy. Drs. Rachel Simpson and Roya Garakani share pearls on patient selection, technique, and postoperative care.

🎥 Watch the full video for practical surgical insights here: https://ow.ly/ta8F50XNfKu

12/23/2025

What's now and what's next in glaucoma? Find out now with the Glaucoma Pipeline 2026 poster, a comprehensive overview of approved and investigational treatment options.

Learn More Here: https://ow.ly/CRRL50XNoxZ

12/22/2025

Catch up on your favorite MIGS Unplugged episodes! It’s been an incredible year of innovation in the ever-evolving glaucoma space, so take a moment to revisit the conversations and expert insights that surrounded it. See you in 2026!

Watch here: https://ow.ly/qQEO50XARyv

12/17/2025

A new case report from Dr. Blake Williamson highlights how interventional glaucoma strategies can benefit patients undergoing cataract surgery. In this case, a 73-year-old patient with cataracts and intermediate POAG received bilateral iDose TR during cataract surgery.

Read here: https://ow.ly/XaIa50XJOCS

12/11/2025

In this episode, Mohamed M. Khodeiry, MD, MSc, recaps the article, “Glaucoma Intrascleral Tube Surgery,” which was featured in GT and covers the surgical modification known as GITS, which may address postoperative complications associated with subconjunctival stent implantation.

Listen Here: https://ow.ly/lhNm50XHAUP

11/24/2025

Drs. Rachel Simpson and Roya Garakani share their expert perspectives on the iDose TR procedural pharmaceutical. Learn how iDose can support patients with poor drop adherence, minimize ocular surface side effects, and offer flexibility as a standalone or combination procedure.

🎥 Watch now to gain practical pearls for patient selection and implantation: https://ow.ly/9TqJ50Xx3ih

11/19/2025

Third-party contracts quietly determine far more of your glaucoma practice’s future than most clinicians realize—from reimbursement stability to patient access and long-term growth.

These five strategies from Ashley R. Geary, Esq highlight where you actually have leverage, and how to renegotiate on terms that protect both your practice and your patients:

These best practices can help you strategize negotiations and maximize your leverage.

11/13/2025

In this episode, Rachel Chapman recaps the article, “Tube Erosion,” which was recently featured in Glaucoma Today. Listen as she reviews rates, risk factors, prevention strategies, and management techniques for tube erosion—a complication of glaucoma drainage implant placement. Link in bio to hear more: https://ow.ly/ON6b50XriB4

11/11/2025

Case Presentation: A 68-year-old woman with advanced glaucoma in her only seeing eye (−19.50 D, axial length 30.5 mm) presents with IOP 32 mm Hg on maximal therapy.

BCVA 20/80 (potential 20/30). Findings: moderate nuclear sclerotic cataract, myopic macular degeneration, marked optic disc cupping (0.9 C/D), severe field loss, and diffuse zonulopathy.

Would you proceed with surgery, and which approach would you choose given her axial length, zonular weakness, and limited visual reserve?

👉 Read the full discussion: https://ow.ly/zSMP50Xq9yE

Case prepared by Devesh K. Varma, MD, FRCSC

Surgical planning in a high-stakes case.

11/06/2025

In a series of articles, leaders in ophthalmology innovation speak about the future of the field. In Visionary Breakthroughs, experts share their thoughts on the most exciting developments that are redefining the future of glaucoma care. https://ow.ly/qi5n50XnrmC

11/06/2025

In a series of articles, leaders in ophthalmology innovation speak about the future of the field. In Visionary Breakthroughs, experts share their thoughts on the most exciting developments that are redefining the future of glaucoma care. Read more by clicking the link in our bio!